Hematologic Malignancy
Mantle Cell Lymphoma
CI-CAN-00005962MCLExplore in graph →
Hematologic180 active trials5 approved drugs7 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005962MCLExplore in graph →
Clinical trials
706 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (121)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06255704 | A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients(Z+RCHOP/RDHAP) | not yet recruiting | Phase 2 | 23 | Shanxi Province Cancer HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05214183 | Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma(ALTAMIRA) | active not recruiting | Phase 2 | 81 | Nordic Lymphoma GroupNETWORK |
| 5 |
| Feb 12, 2024 |
| clinicaltrials |
| NCT03684694 | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma | terminated | Phase 1 / Phase 2 | 136 | ADC Therapeutics S.A.INDUSTRY | 6 | Feb 6, 2024 | clinicaltrials |
| NCT04858568 | Immune Responses to COVID-19 Vaccination in Lymphoma Patients(PROSECO) | completed | — | 592 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | terminated | Phase 1 | 21 | Prelude TherapeuticsINDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | terminated | Phase 1 | 3 | Stanford UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03833180 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | completed | Phase 1 | 91 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jan 12, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05833763 | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.(GOlDiLOX) | recruiting | Phase 2 | 42 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04718883 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma | active not recruiting | Phase 2 | 59 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT01523223 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | completed | Phase 1 | 16 | Robert LowskyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02728531 | Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma | completed | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT02869633 | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant | completed | Phase 2 | 23 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03188965 | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 | 229 | BayerINDUSTRY | 7 | Oct 11, 2023 | clinicaltrials |
| NCT01035463 | Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 74 | University of NebraskaOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03616782 | Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) | unknown | Phase 2 | 98 | Ho Sup LeeOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT01000753 | Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma | completed | — | 174 | Children's Oncology GroupNETWORK | 4 | Oct 3, 2023 | clinicaltrials |
| NCT00571493 | VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 42 | University of NebraskaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04692155 | Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)(CHOP U2) | terminated | Phase 1 / Phase 2 | 1 | University of Alabama at BirminghamOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06049472 | Patient Perspectives in Mantle Cell Lymphoma Clinical Research | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT01739309 | Study of LY2835219 for Mantle Cell Lymphoma | completed | Phase 2 | 28 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 21, 2023 | clinicaltrials |
| NCT02661035 | Allo HSCT Using RIC for Hematological Diseases | completed | Phase 2 | 156 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05917964 | A Food Effect Study of LP-168 Tablets in Healthy Subjects | completed | Phase 1 | 22 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Sep 11, 2023 | clinicaltrials |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | terminated | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT04231734 | Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma | withdrawn | N/A | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT02471391 | ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)(AIM) | unknown | Phase 2 | 37 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT01484093 | Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 96 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT03229382 | Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse(OPERA-PLRG10) | terminated | Phase 2 | 1 | Polish Lymphoma Research GroupNETWORK | 1 | Aug 16, 2023 | clinicaltrials |
| NCT03010358 | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 24 | Alexey Danilov, MDOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT01652144 | A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma | completed | Phase 2 | 12 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01267812 | Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation | completed | Phase 2 | 23 | City of Hope Medical CenterOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT03219047 | Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma | completed | Early Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05020392 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | unknown | Phase 3 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | terminated | Phase 1 | 2 | ExelixisINDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05934097 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | withdrawn | Phase 1 | 0 | Fate TherapeuticsINDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | terminated | Early Phase 1 | 2 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT01029366 | CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy | completed | Phase 1 | 26 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 51 | Asana BioSciencesINDUSTRY | 2 | Jun 7, 2023 | clinicaltrials |
| NCT05888701 | "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. | unknown | — | 30 | University of Milano BicoccaOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT02632396 | Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission | unknown | Phase 1 / Phase 2 | 12 | Emory UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | terminated | Phase 1 | 97 | MEI Pharma, Inc.INDUSTRY | 2 | May 9, 2023 | clinicaltrials |
| NCT05431179 | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | withdrawn | Phase 3 | 0 | Oncternal Therapeutics, IncINDUSTRY | 0 | Apr 21, 2023 | clinicaltrials |
| NCT00783367 | Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas | completed | Phase 2 | 50 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT02840539 | Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma(BATMAN) | completed | Phase 2 | 19 | Seoul National University HospitalOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04323657 | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 6 | TCR2 TherapeuticsINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT00644189 | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Feb 13, 2024source: clinicaltrials